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factor that signiﬁcantly correlated with the risk of RILT (P = 0.035, 
OR = 2.354). If patients were grouped based on high or low TGF-β1 
ratio (during RT/pre-RT), 13 out of the 29 patients with a TGF-β1 ratio 
higher than the median level of 0.8 developed RILT, while only 5 out 
of the 35 patients with low TGF-β1 ratios developed RILT (P = 0.007). 
No signiﬁcant correlation was seen between TGF-β1 ratio and MLD or 
between TGF-β1 ratio and the decline in DLCO
Conclusion: An increase in plasma TGF-β1 level during RT may be 
predictive of RILT. The potential use of TGF-β1 levels during RT to 
adapt RT delivery deserves further study.
PD5-1-6 Technical Advances on Radiation Therapy, Thu, 12:30 - 14:15
Combination of serum cytokine with lung DVH for prediction 
radiation pneumonitis
Ji, Wei 
Cancer Hospital CAMS (Chinese Academy of Medical Science),  
Beijing, China
Objective: To study the relationship between level of plasma transform 
growth factor bata (TGF-beta), interleukin (IL-6), angiotensin-convert-
ing enzyme (ACE) and physical parameters (V10, V15, V20, MLD) 
and radiation pneumonitis (RP). 
Methods: The records of all patients with lung cancer treated with 
radiotherapy (RT) with curative intent from February 2004 to August 
2005. A total of 67 patients were identiﬁed who met the following 
inclusion criteria: (1) newly diagnosed lung cancer of any histology 
treated with RT± chemotherapy with curative intent; (2) a Karnofsky 
performance status >70; (3) expected survival >6 months; (4) follow-
up time more than 6 months; (5) no pneumonectomy. Blood samples 
were collected and measured with enzyme-linked immunosorbent assay 
(ELISA). TGF-beta, IL-6 and ACE measurements obtained before RT 
(Pre-RT) and when RT dose reached 40-50Gy (during-RT). Fifty-eight 
patients were treated with computed tomography based 3-dimensional 
planning and had dose-volume histogram data available. The endpoint 
of the study was the development of ≥ grade 2 RP (NCI [National Can-
cer Institute] common toxicity criteria 3.0). 
Results: The Median follow-up time of the alive patients is 22.6 
months. The incidence of ≥ grade 2 RP for all 67 patients was 25.4%. 
Between the RP and non-RP group, there was no difference in Pre- or 
during- RT level of TGF-beta, IL-6. We observed ACE level was lower 
in RP group than in the non-RP group, both pre-RT and during-RT 
(p=0.033 and p=0.004). Fifty-eight patients received 3-dimensional 
conformal RT (3DCRT). In RP group, patients are received higher all 
lung V10, contra lateral MLD, contra lateral V10, contra lateral V15, 
contra lateral V20 (44% vs 39%, 1931cGy vs 990cGy, 52% vs 35%, 
48% vs 27%, 37% vs 10% P< 0.05). The subgroup of 54 patients 
treated with 3DCRT and the data of ACE level were available, were 
divided into groups according to their plasma ACE median level and 
whether their V10 level was above or below the median of 40%; Group 
I (n=13), with ACE > 506ng/ml and V10 ≤ 40%; Group II (n=30), with 
ACE > 506ng/ml and V10 > 40%; ACE ≤ 506ng/ml and V10 ≤ 40%; 
Group III (n=12), with ACE ≤506ng/ml and V10 > 40%. A signiﬁcant 
different was found in the incidence of RP among these three groups 
(0%, 26.7%, 50.0% p=0.008) 
Conclusions: (1) A lower plasma ACE level during-RT is an indepen-
dent risk factor for RP; (2) The combination of plasma ACE level and 
V10 appears to facilitate stratiﬁcation of patients into three groups. 
Thus, combining both physical and biologic risk factors may allow for 
better identiﬁcation of patients at risk for the development of symptom-
atic radiation-induced lung pneumonitis.
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Time trends in nodal CT volume and nodal motion during 
radiotherapy for patients with stage III non-small cell lung cancer
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Stofferinus Boersma, Liesbeth Lambin, Philippe De Ruysscher, Dirk 
Department of Radiation Oncology (MAASTRO), GROW, University 
Hospital, Maastricht, The Netherlands
Background: Knowledge of changes in volume and motion of either 
tumor or involved lymph nodes during a course of radiotherapy is nec-
essary to improve the treatment (adaptive radiotherapy). These changes 
for the primary tumor were already reported (Bosmans et al, Int J 
Radiat Oncol Biol Phys, 2006). The purpose of this study is describing 
the time trends in nodal CT volume and nodal motion, for patients with 
locally advanced non-small cell lung cancer.
Methods: Eleven patients, with a total of 21 nodes, from a prospective 
clinical trial underwent CT-PET scans prior to treatment, which was 
repeated in the ﬁrst and second week following the start of radiothera-
py. For 20 nodes, the motion could be measured based on a respiration 
correlated CT (RCCT) scan. Moreover, repeated RCCT scans were 
available for 11 nodes to evaluate the change in motion. Patients were 
treated with an accelerated fractionation schedule, 1.8 Gy BID, with 
a total tumor dose depending on pre-set dose constraints for the lungs 
and the spinal cord. 
Results: A heterogeneity of nodal volume changes was observed at all 
time points similar to the tumor volume changes. In some patients the 
nodal volume increased > 50% (4/21) in others the volume decreased 
> 50% (1/21) but for the majority of nodal areas (16/21) the volume 
only changed slightly (< 50%). The initial absolute nodal volume was 
4.5 cc ± 4.3 cc, therefore large volume changes were observed and the 
delineation of small volumes is sensitive to intra-observer variability. 
On average the nodal volume did not change signiﬁcantly (4.5, 4.9 
and 4.3 cc prior to treatment, 1 and 2 weeks after the start of treatment 
respectively). The 3D vector motion, which is the quadratic sum of the 
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orthogonal movements, of the nodal areas was initially 5.7 mm ± 2.9 
mm, which was somewhat smaller than the tumor motion (7.8 mm ± 
4.8 mm). The motion of the lymph nodes decreased during therapy (5.8 
mm after 1 week and 5.3 mm after 2 weeks) but was not statistically 
signiﬁcant different. No difference in motion and motion changes was 
observed between the locations of the lymph nodal areas.
Conclusion: A large variability of changes in nodal volume between 
the patients was observed, but is not clinically relevant since the vol-
umes and hence the volume changes are small. The motion of the nodal 
areas is smaller than the tumor motion and does not change during 
therapy. Therefore smaller internal margins can be applied for the nodal 
areas compared to the internal margin for the primary tumor.
PD5-1-8 Technical Advances on Radiation Therapy, Thu, 12:30 - 14:15
4D CT imaging impacts lung volume definitions and dose-volume 
relationships in radiation treatment of non-small cell lung cancer
Kang, Yixiu; Bucci, M. Kara; Liao, Zhongxing; Liu, Helen H.; Tucker, 
Susan L.; Chang, Joe Y.; Komaki, Ritsuko; Cox, James D.; Mohan, 
Radhe; Dong, Lei 
M.D. Anderson Cancer Center, Houston, TX, USA
Purpose: To characterize lung volume deﬁnitions at various CT 
imaging conditions for advanced non-small-cell lung cancer (NSCLC) 
patients. Due to respiratory motion, lung volumes measured by CT im-
aging can exhibit signiﬁcant volumetric variations, which can affect the 
assessment of dose-volume relationships for radiotherapy. The goal of 
this study was to quantify the range of uncertainties in the dose-volume 
relationships and suggest a uniﬁed correction procedure. 
Methods: Forty stage III/IV NSCLC patients were randomly selected 
for this study. For all patients, a fast CT scan and a 4D CT scan were 
acquired under natural breathing conditions. The fast CT scan (free 
breathing, or FB) represents the typical clinical practice for CT-based 
radiotherapy treatment planning. The 4D CT scan represents the state-
of-art volumetric imaging technique to explicitly include respiratory 
motion. We deﬁne the lung volumes measured in 4D CT at the end of 
inspiration and at the end of expiration as end inspiratory volume (EIV) 
and end expiratory volume (EEV), respectively. The percent of vol-
umes at 5Gy (V5), 20Gy (V20), and 50Gy (V50) were calculated and 
compared for each volume deﬁnition at FB, EEV, EIV, and a specially 
computed average density volume from 4D CT. 
Results: The total lung EIV was on average 13.9% larger than the EEV 
(1SD 5.1%; range: 5.7% to 28%). While the average density of the 
lung at the end of inspiration was 8% lower than the density of the lung 
at the end of expiration, the total mass enclosed in the lung volume 
was 4.6% higher at the end of inspiration than at the end of expira-
tion, possibly due to the blood inﬂow caused by the negative pressure. 
There was an excellent linear relationship between the density ratio 
and the volume ratio at the two breathing extremes among all patients 
(R=0.86; p<0.0001). We found a strong volume impact to the dose-vol-
ume relationship. The V5, V20, and V50 between EIV and EEV varied 
from -15% to +12%, -21% to +17%, and -6% to +3%, respectively. 
The V5, V20, and V50 deﬁned on FB CT scans were systematically 
smaller than those deﬁned in EEV (average=-1.9% for V5; -1.3% for 
V20; and -0.8% for V50) and varied signiﬁcantly (range from -12% to 
+1%), representing the uncertainties in the dose-volume analysis. These 
variations were primary due to volume differences at different breath-
ing phases. The impact of dose distribution by anatomy changes was 
minimal (V5, V20, and V50 variations were less than 1% for the same 
volume deﬁnition). We found that the use of a simple scaling factor can 
effectively correct or convert the dose-volume parameters from one 
phase to another using the population data obtained in this study.
Conclusions: Signiﬁcant variations in dose-volume parameters were 
found in current practice when using different volume deﬁnitions. 
We recommend reporting dose-response data on standardized volume 
deﬁnitions (such as the end of expiration, which is more nature for indi-
vidual patients). Parameters found in this study can be used to convert 
these dose-volume parameters from one volume deﬁnition to another 
based on population average.
PD5-2-1 Clinical Data from Radiation Therapy, Thu, 12:30 - 14:15
Effective local control of stage III non-small cell lung cancer 
(NSCLC) with accelerated radiotherapy for patients with 
unfavorable prognostic factors
Ohnishi, Kayoko; Komaki, Ritsuko; Alen, Pamela; Cox, James; Wei, 
Xiong; Liao, Zhongxing 
The UT, MD Anderson Cancer Center, Houston, TX, USA
Purpose: This retrospective study was performed to evaluate the ef-
ﬁcacy and toxicity of accelerated radiotherapy for patients with Stage 
III NSCLC with unfavorable prognostic factors (PF). 
Materials and Methods: Between 1994 and 2004, 113 patients with 
Stage III NSCLC and unfavorable PF were treated with accelerated 
radiotherapy of 45 Gy in 15 fractions over 3 weeks at the University of 
Texas M.D. Anderson Cancer Center. To compare the efﬁcacy of accel-
erated radiotherapy with conventional radiotherapy, 222 patients with 
Stage III NSCLC who received conventional radiotherapy of >60 Gy 
between 1987 and 2005 were identiﬁed. Their medical and radiological 
records were retrospectively reviewed and analyzed for overall survival 
(OS), local-regional control (LRC), disease free survival (DFS) and 
distant metastasis-free survival (DMFS). Acute and late toxicity of 
accelerated radiotherapy with regard to esophagus and lung were also 
analyzed.
Results: Compared to the patients treated with conventional radio-
therapy, the patients treated with accelerated radiotherapy were older 
in age, had poorer PF and received less chemotherapy. The median 
age was 67 (P<0.00001), 91 patients (81%) had a weight loss of >10% 
(P<0.0001) and 43 patients (38%) had Karnofsky performance status 
(KPS) <70 (P<0.0001). 75 patients (66%) received no chemotherapy. 
Median follow-up was 10 months for the accelerated group and 13 
months for the conventional radiotherapy group. OS was statistically 
